MyMIWallet

OTLK Breakout Stock Alert Update

NASDAQ:OTLK   Outlook Therapeutics, Inc.
BREAKOUT STOCK ALERT UPDATE
$OTLK - Outlook Therapeutics, Inc. - Common Stock (CV EM)
Initial Alert Price: $1.32
Price High: $1.03
% Gains/Losses: -21.97%
(-41.7% Less Than Expected)
Potential Stop Loss: $0.9785


OTLK recently announced a $35 Million Common Stock Offering which cause the stock to drop 20% during today's pre-market session. We would stand to suggest one of two options here.

Option 1:
Hold until the stock offering closes, allowing the stock to rebound back to higher price levels. It is key to keep in mind that it is not a bad when a company provides a common stock offering to access more liquidity as needed (which is the whole purpose of a company being publicly traded to begin with) in order to ramp up operations.

Option 2:
Cut your loses and move on the next trade.

With that being said, we are currently not closing this trade just yet in order to allow for the stock offering to come to a close. The stock actually jumped to $1.40 for a 6% gain from our original trade alert, which was -13% less than our target gains on the trade. So we're going to let this play out as it's only $0.38 below our initial entry price on the trade, but it may require a longer hold in order to profit from the gain. The stock is currently showing a reversal on the 1-Hr. as it is oversold on that timeframe. Keep an eye on this moving forward in order to make sure we don't dip below that $0.92 Price Levels moving forward. We have alerts set to push out a sell alert if deemed necessarily to protect further loses. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today

Tim Burks | Founder - MyMI Wallet
Empower your finances with our Personal Budgeting and Investment Forecasting Tools. Unlock your investment potential today at MyMI Wallet.
www.mymiwallet.com
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.